The company had posted a net profit of Rs 113.08 crore in the same period of the previous fiscal.
During the quarter, Biocon reported exceptional gain of Rs 105.06 crore on account of share sale in its research services subsidiary Syngene.
Net sales of the company rose to Rs 830.38 crore for the quarter, up 14.91 per cent against Rs 722.59 crore for the same period a year ago, Biocon said in a statement.
On future outlook Shaw said, "As we move into FY16, we are clearly seeing our biosimilar strategy playing out with greater clarity, credibility and traction visible across our portfolio of Biologics as they advance in clinical development. We continue to make investments in R&D as a strong future value driver."
The company's net sales for the year rose to Rs 3,059.97 crore, up 7.26 per cent against Rs 2,852.72 crore in the previous year.
Biocon shares were trading at Rs 456.40 a piece on the BSE, up 3.04 per cent from its previous close.